Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health Inc (OPK) maintains this comprehensive news hub for investors and healthcare professionals tracking developments in precision diagnostics and therapeutic innovation. Our curated collection features official press releases, regulatory filings, and verified third-party analysis of OPKO's advancements in genetic testing platforms and pharmaceutical research.
This resource serves as a centralized repository for monitoring strategic initiatives across OPKO's core segments: clinical diagnostics through BioReference Health laboratories, and pharmaceutical development targeting metabolic disorders and chronic conditions. Users will find updates on clinical trial progress, partnership announcements, and operational milestones within the company's global supply network.
Key content categories include earnings reports, product pipeline developments, FDA regulatory updates, and strategic business decisions. The page is regularly updated to reflect OPKO's evolving position in healthcare markets while maintaining historical context for longitudinal analysis.
Bookmark this page or set news alerts to stay informed about OPKO Health's contributions to diagnostic technology and targeted therapies. For verified information directly from corporate sources, we recommend cross-referencing filings with official SEC documentation.
OPKO Health (NASDAQ: OPK) has announced it will release its Q1 2025 financial and operating results on April 30, 2025 after U.S. market close. The company's senior management will host a conference call and live audio webcast at 4:30 p.m. Eastern time to discuss the results and provide financial guidance.
Participants can pre-register for the conference call through a provided link to receive a unique PIN for immediate access. Those unable to pre-register can dial 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast replay will be available approximately one hour after the call until May 7, 2025.
NextPlat Corp (NASDAQ: NXPL) announced it will pause certain initiatives within its e-Commerce development program due to increased US/China tariffs on US-produced goods. The company is specifically halting plans for its Florida Sunshine brand of vitamins and supplements in the Chinese market, as the tariffs would significantly impact import costs and competitive positioning against local products.
Despite these challenges, NextPlat will continue selling OPKO Health Europe (OPKO) products in China, including nutraceuticals, supplements, and pet care items, as these are not US-produced and therefore not subject to the additional tariffs. The company is exploring opportunities to sell Florida Sunshine products in other markets.
OPKO Health (NASDAQ: OPK) has announced a $100 million increase to its existing share repurchase program, bringing the total program capacity to $200 million. The company has already repurchased approximately $41 million of common stock since the program's initial authorization in July 2024.
The expanded buyback program, representing about 14% of shares outstanding at current price levels, will be executed through various methods including open market purchases, block trades, and accelerated share repurchase transactions. OPKO had approximately 671.6 million shares outstanding as of February 24, 2025.
The company plans to fund the repurchases from existing cash reserves and future cash flows. The program has no time limit and can be modified or suspended at management's discretion based on market conditions and other factors.
OPKO Health (NASDAQ: OPK) and Entera Bio have formed a collaboration agreement to develop the first oral dual agonist GLP-1/glucagon peptide tablet for treating obesity and metabolic disorders. The program combines OPKO's long-acting oxyntomodulin analog (OPK-88006) with Entera's N-Tab™ technology.
The partnership structure gives OPKO a 60% ownership stake and Entera 40%, with corresponding cost-sharing responsibilities. OPKO has purchased 3,685,226 Entera shares at $2.17 per share, with proceeds funding Entera's Phase 1 development costs. After Phase 1, Entera can maintain its 40% stake by continuing funding, or opt-out to retain 15% ownership while OPKO increases to 85%.
The companies reported favorable pharmacodynamic, pharmacokinetic, and bioavailability data in September 2024 and plan to file an FDA Investigational New Drug application later in 2025. The treatment aims to suppress appetite, induce weight loss, and provide cardioprotective and anti-fibrotic benefits through its novel dual-action mechanism.
Labcorp (NYSE: LH) has announced an agreement to acquire select assets of BioReference Health's oncology and oncology-related clinical testing services from OPKO Health. The transaction, valued at up to $225 million, includes $192.5 million at closing and a potential $32.5 million performance-based earnout.
The acquired assets generate $85-100 million in annual revenue and will expand Labcorp's oncology diagnostic testing portfolio across the United States. The deal is expected to be earnings accretive in the first year and close in the second half of 2025.
Post-acquisition, BioReference Health will maintain its core clinical testing operations in the New York and New Jersey region, including its 4Kscore franchise, which generated approximately $300 million in revenue for 2024.
OPKO Health (NASDAQ: OPK) reported its Q4 2024 financial results with consolidated revenues of $183.6 million, up from $181.9 million in Q4 2023. The company achieved a net income of $14.0 million ($0.01 per diluted share), compared to a net loss of $66.5 million in the prior year.
Key highlights include Merck's Phase 1 Epstein-Barr virus vaccine trial initiation, $51 million in additional BARDA funding for COVID and influenza programs, and ongoing enrollment in the MDX2001 Phase 1 cancer trial. The company's diagnostics segment, BioReference Health, progressed toward profitability through cost reductions and asset sales.
OPKO strengthened its capital structure by repurchasing $17.0 million of convertible notes and 10.9 million common shares. The company ended Q4 2024 with $431.9 million in cash and equivalents, plus $54.6 million in marketable securities.
OPKO Health (NASDAQ: OPK) has announced it will release its fourth quarter and full-year 2024 financial results on February 27, 2025, after U.S. market close. The company will host a conference call and live audio webcast at 4:30 p.m. Eastern time on the same day, where senior management will provide a business update, discuss results, and share financial guidance.
Participants can pre-register for the conference call through a provided link to receive immediate access. Those unable to pre-register can dial 833-630-0584 (U.S.) or 412-317-1815 (International). A telephone replay will be available until March 6, 2025, and a webcast replay will be accessible approximately one hour after the live call.
OPKO Health (Nasdaq: OPK) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, at the Westin St. Francis hotel in San Francisco.
The company's management will conduct one-on-one meetings with investors and deliver a presentation on Wednesday, January 15th at 3:00 p.m. Pacific time. Interested parties can access the live webcast and replay of the presentation through the Investors section of OPKO Health's website.
OPKO Health's subsidiary ModeX Therapeutics has initiated Phase I clinical trials for an Epstein-Barr virus (EBV) vaccine candidate in collaboration with Merck. The first participant has been dosed in the study (NCT06655324), which will evaluate the safety and tolerability of MDX2201 in up to 200 healthy adults. This milestone triggers an undisclosed cash payment from Merck to ModeX.
The vaccine candidate targets multiple viral proteins and aims to stimulate protective immunity against EBV, which causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosis. Currently, there are no approved treatments or vaccines for EBV. The collaboration leverages Merck's clinical development expertise with ModeX's innovative technology platform to address this latent virus that affects a majority of the global population.
NextPlat Corp (NASDAQ: NXPL) has received vendor approval from JD.com, China's largest self-operated e-Commerce retailer, to list and sell OPKO Health Europe branded health & wellness and veterinary care products. The company plans to launch products on JD.com in Q1 2025, accessing over 340 million consumers.
The initiative includes listing OPKO human health products such as nutraceuticals for bone and joint health, and supplements for nutrition and immunity. Subject to Chinese regulatory clearance expected in Q1 2025, NextPlat plans to expand offerings to include veterinary and animal health products. This expansion comes as China's nutraceuticals market is projected to reach $100 billion by 2025.
The company has already begun online and offline marketing in China and recently participated in the 2024 China International Natural Health & Nutrition Expo (NHNE).
